ArticleDermatology and therapy2023

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.

Michael J Cork et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.